Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rupa Narayan

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Blood Advances|September 23, 2022
Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignanciesAmir T Fathi, Haesook T Kim, Robert J Soiffer, et al.
Blood Advances|February 27, 2025
Integrative cytogenetic and molecular studies unmask "chromosomal mimicry" in hematologic malignanciesMelissa Zhao, Scott Ryall, Samuel J Brody, et al.
British Journal of Haematology|July 13, 2026
Clinical outcomes of combination treatment with FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in patients with acute myeloid leukaemiaCatherine Gutierrez Moore, Donian I Chyong, Naval Daver, et al.
Transplantation and Cellular Therapy|March 30, 2023
HLA Class I Genotype Is Associated with Relapse Risk after Allogeneic Stem Cell Transplantation for NPM1-Mutated Acute Myeloid LeukemiaRupa Narayan, Abhishek Niroula, Tao Wang, et al.
Leukemia & Lymphoma|March 12, 2025
Ixazomib in addition to chemotherapy for the treatment of acute myeloid leukemia in older adultsPhilip C Amrein, Frederic I Preffer, Geoffrey Fell, et al.
American Journal of Hematology|November 23, 2023
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromesAndrew M Brunner, Jordi Esteve, Kimmo Porkka, et al.
Cancer|December 21, 2019
A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemiaRupa Narayan, Traci M Blonquist, Ashkan Emadi, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Blood Advances|September 23, 2022
Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignanciesAmir T Fathi, Haesook T Kim, Robert J Soiffer, et al.
Blood Advances|February 27, 2025
Integrative cytogenetic and molecular studies unmask "chromosomal mimicry" in hematologic malignanciesMelissa Zhao, Scott Ryall, Samuel J Brody, et al.
British Journal of Haematology|July 13, 2026
Clinical outcomes of combination treatment with FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in patients with acute myeloid leukaemiaCatherine Gutierrez Moore, Donian I Chyong, Naval Daver, et al.
Transplantation and Cellular Therapy|March 30, 2023
HLA Class I Genotype Is Associated with Relapse Risk after Allogeneic Stem Cell Transplantation for NPM1-Mutated Acute Myeloid LeukemiaRupa Narayan, Abhishek Niroula, Tao Wang, et al.
Leukemia & Lymphoma|March 12, 2025
Ixazomib in addition to chemotherapy for the treatment of acute myeloid leukemia in older adultsPhilip C Amrein, Frederic I Preffer, Geoffrey Fell, et al.
American Journal of Hematology|November 23, 2023
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromesAndrew M Brunner, Jordi Esteve, Kimmo Porkka, et al.
Cancer|December 21, 2019
A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemiaRupa Narayan, Traci M Blonquist, Ashkan Emadi, et al.
Pageof 3